What is Tarsus Pharmaceuticals, Inc.'s Shariah compliance score?

Tarsus Pharmaceuticals, Inc. (TARS) has a Shariah compliance score of 62/100 (Grade: B, Acceptable) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Tarsus Pharmaceuticals, Inc. pass AAOIFI screening?

Tarsus Pharmaceuticals, Inc. (TARS) partially passes with caution AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (TARS: 2.8%), (3) interest-bearing deposits below 30% (TARS: 16.0%), and (4) prohibited income below 5% (TARS: 4.4%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Tarsus Pharmaceuticals, Inc. stock?

Tarsus Pharmaceuticals, Inc. (TARS) has a non-permissible income ratio of 4.41%. Muslim investors should purify this percentage of any dividends received and capital gains realized from TARS shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Tarsus Pharmaceuticals, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Tarsus Pharmaceuticals, Inc. (TARS) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about TARS's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is Tarsus Pharmaceuticals, Inc. (TARS) halal? Doubtful. Based on AAOIFI screening, Tarsus Pharmaceuticals, Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 62/100 (Grade: B).

TARS: Is Tarsus Pharmaceuticals, Inc. Halal?

Doubtful

Tarsus Pharmaceuticals, Inc.

NASDAQHealthcareUS

$60.80

-1.70%

AvoidBorderlineClean

Purify ~4.4% of income

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

Sector: Healthcare · Industry: Biotechnology

Why This Stock Is Doubtful

Non-compliant income is 4.4% of revenue, only 0.6 points below the 5% limit

Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 17, 2026

Acceptable

Acceptable but room for improvement

62Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Passed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap2.8% / 30.0%

Compliance History

Doubtfulnow
since Jun 2026
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 17, 2026Fiscal: Q1 2026Source: FMP

Purify Your TARS Dividends

4.4% non-compliant income

TARS has 4.4% prohibited income. Calculate exactly how much of your dividends to donate.

Financial Overview

Market Cap

2.6B

Price

$60.80

Sector

Healthcare

Industry

Biotechnology

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track TARS and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Tarsus Pharmaceuticals, Inc. (TARS) halal to invest in?

Tarsus Pharmaceuticals, Inc. (TARS) is rated Doubtful under AAOIFI Standard 21. It passes the business activity screen but one or more financial ratios are approaching (though not yet exceeding) the AAOIFI thresholds (30% for debt and interest deposits, 5% for prohibited income). Consult a qualified Islamic finance scholar for a personal ruling.

Why did Tarsus Pharmaceuticals, Inc. get a B compliance rating?

Tarsus Pharmaceuticals, Inc. (TARS) received a grade of B (Acceptable) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 2.8% (limit 30%); interest-bearing deposits of 16.0% (limit 30%); prohibited income of 4.41% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Tarsus Pharmaceuticals, Inc.'s Shariah verdict?

Tarsus Pharmaceuticals, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Tarsus Pharmaceuticals, Inc. re-screened for Shariah compliance?

Tarsus Pharmaceuticals, Inc. (TARS) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 17, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.